Skip to main content

Jhunjhunwala among proposed investors for VA Tech Wabag's Rs 120-crore Preferential Issue

 Rekha Rakesh Jhunjhunwala will likely be issued up to 50 lakh shares for Rs 80 crore, Basera Home Finance Private Limited will pick up 15 lakh at Rs 24 crore and Sushma Anand Jain & Anand Jai will get 10 lakh shares at Rs 16 crore.

VA Tech Wabag is planning to raise Rs 120 crore from three marquee investors, including Rekha Jhunjhunwala (wife of ace investor Rakesh Jhunjhunwala).

In an exchange filing, the Chennai-based water and sewage treatment company said its board had considered equity infusion on a preferential basis at Rs 160 apiece, which is at 30 percent discount to the stock’s closing price on August 25.

Rekha Rakesh Jhunjhunwala will be issued up to 50 lakh shares for Rs 80 crore, Basera Home Finance Private Limited will pick up 15 lakh at Rs 24 crore and Sushma Anand Jain and Anand Jai will get 10 lakh shares at Rs 16 crore.

"This is the first time the company has proposed to raise equity capital since its IPO in 2010 and we believe that this well-timed equity infusion will provide the necessary growth capital for the company to scale greater heights. We look forward to a long-term association with each of the potential incoming investors," MD & Group CEO Rajiv Mittal said.

With its technology focus, asset-light model and global presence, the company is well-positioned to consolidate its leadership in the water technology sector, he said.

In the backdrop of growing awareness and need for sustainable businesses, across the world, the company is an ideal destination for global investors, especially for ESG focused investors, Mittal said.

Despite the approval of equity infusion plans, shares of VA Tech Wabag were trading at Rs 223, down 1.89 percent on the BSE.

The stock touched an intraday high of Rs 235 and an intraday low of Rs 210.10. On a year-to-date basis, it is up nearly 22 percent.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Indigo Paints trades at over 55% premium in grey market after IPO price announcement

The grey market premium has increased significantly from Rs 400-500 on January 11 to Rs 840-850 on January 15. Indigo Paints, one of the fastest-growing paint companies in India, was trading at more than 50 percent premium over its higher issue price band of Rs 1,490 per share in the grey market after the announcement of IPO details. The premium in the grey market as of January 15 was at around Rs 840-850 per share, which means the grey market trading price stood at Rs 2,340-2,330 against the issue price of Rs 1,490, as per the data available on IPO Watch. The premium increased significantly from Rs 400-500 on January 11 to Rs 840-850 today. The grey market is an unofficial trading platform where shares get traded well before the allotment in an initial public offering and till the shares get listed on bourses. It generally estimates the expected listing price of a stock. "Currently Asian paints and Berger paints are trading at a PE of 111 and 148, respectively, while Indigo Paint...